Fantastic description of targeted therapy in the early stage lung cancer space from Dr. Mariam Alexander at #DCLung24. Striking benefit for targeting #EGFR and #ALK after surgery but looking ahead, likely to see impact in other targets and in the neoadjuvant setting.

Fantastic multi-disciplinary panel to discuss early stage NSCLC at #DCLung24 with Drs. Stephen R Broderick MD MPHS, Charu Aggarwal, MD, MPH, FASCO, Marc Margolis, Jon Lishcalk, Mariam Alexander, Ryan Gentzler, MD, Tina Cascone.

Advances in molecular targets for NSCLC - Dr. Nagla Abdel Karim Mariam Alexander Stephen V Liu, MD MUSC Health oncodaily.com/url/169256.html #NSCLC #Cancer #MedEd #MedNews #Health #Medicine #MedTwitter #OncoDaily #Oncology

Get ready for 'Tools for Tomorrow’s Oncologist' at #TexasLung25 starting at 3:30 PM with special guests Drs. Steven Paulson and Dr. Patt and other leading experts. Raymond Osarogiagbon, MBBS, FACP Jill Feldman Narjust Florez, MD, FASCO hubs.la/Q03g5QJD0

Thanks Stephen V Liu, MD #TinaCascone TLC Conference for the invitation to speak about ICI toxicities and hang out with the coolest of the cool group #TexasLung25 #lcsm Jill Feldman Narjust Florez, MD, FASCO Raymond Osarogiagbon, MBBS, FACP #JenTemel @Ideologyhealth MUSC Hollings Cancer Center MUSC Health Hematology & Oncology Women Physicians Group—HOWPG

A Sen-sational choice for this important role. Triparna has worked tirelessly to advance our understanding of aggressive lung cancers and will continue to be pivotal in shaping the future of lung cancer research. #lcsm

More options!

We made it to #ASCO25 ⁦ASCO⁩ and running in between sessions & meetings ⁦Ticiana Batista (Leal)⁩ ⁦Mariam Alexander⁩ ⁦Hina Khan⁩ ⁦H. Jack West, MD, FASCO⁩

More options for this rare disease. Would this work after zipalertinib (trial pt) ⁦Balazs Halmos⁩ FDA grants accelerated approval to sunvozertinib for NSCL with EGFR exon 20 insertion mut #lcsm fda.gov/drugs/resource…

Such a treat to discuss this important approval and learn about the history of Sunvozertinib development and trial design and nuances of dose/toxicities from Dr James Yang. Thanks Stephen V Liu, MD IASLC #lcsm EGFR Resisters

The #FDA has approved sunvozertinib for patients with #EGFR exon 20 insertions, but what sets this therapy apart? On #LungCancerConsidered, Stephen V Liu, MD, Mariam Alexander & Dr. James Chih-Hsin Yang break down the data and explore clinical impact. 🎧 bit.ly/FDAexon20

Don't miss #DCLung25 - a one-day, IASLC endorsed comprehensive lung cancer conference on Saturday, October 4th in Washington DC. Joining us will be Dr. Mariam Alexander Mariam Alexander, who will outline antibody drug conjugates (ADCs) in lung cancer. medstarhealth.org/dclung25

Quick pre #DCLung25 visit to the National Portrait Gallery National Portrait Gallery USA - my favorite museum in DC - with some of the faculty!

#DCLung25 Hard-hitting talk on biomarker testing in NSCLC by Christine Lovly, MD, PhD, FASCO, where she highlights: - expanding list of targeted therapy - cannot prescribe, if test is not done - interpreting lung cancer genomic results has become an ‘in the weeds’ skill Wow IASLC #LCSM

Wow. Dr. Jarushka Naidoo gives the #DCLung audience a true master class on immune related toxicities, debunking myths & providing pearls on long-term management. Steroids are not always the preferred initial treatment. Rechallenge possible. Specific irAEs have different prognosis.

#DCLung25 My fellow 🇪🇺 speaker at DCLung Alfredo Addeo MD comprehensively reviews bispecifics, & where they are going in NSCLC. Applications are broad, to: - IO-responsive tumors (eg Ivonescimab) - Oncogene+ tumors (eg izi-bren, EGFR) - the future: bicycles & more! IASLC HUG #LCSM

Beautiful tour of antibody drug conjugates from Dr. Mariam Alexander at #DCLung25 with new approvals of datopotamab deruxtecan in EGFR mutant NSCLC and telisotuzumab vedotin in MET IHC+ NSCLC. Biomarker development critical to optimal use (NMR QCS) and new classes of ADCs coming!

Dr. Mariam Alexander with a comprehensive overview of the symphony of emerging ADCs in lung cancer. Lots of emerging data and smattering of approvals, but ideal biomarkers still needed. #DCLung25

Thank you Stephen V Liu, MD and Joshua Reuss for the kind invitation. Awesome conference. Fun, educational and so well organized

You are our inspiration Balazs Halmos . Also I have not figured out how you manage to be so funny while being educational. It’s an art!